Richard A. Miller 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-13 4:31 pm Purchase | 2025-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Richard A. Miller | 6,085,922 7.800% | 865,554 (+16.58%) | Filing |
| 2025-02-13 4:30 pm Purchase | 2024-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Richard A. Miller | 5,220,368 7.700% | 1,536,358 (+41.70%) | Filing |
| 2024-02-13 6:27 pm Purchase | 2023-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Richard A. Miller | 3,684,010 7.190% | 578,889 (+18.64%) | Filing |
| 2023-02-10 4:00 pm Purchase | 2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Richard A. Miller | 3,105,121 6.450% | 497,973 (+19.10%) | Filing |
| 2022-02-11 5:55 pm Purchase | 2021-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | Richard A. Miller | 2,607,148 5.450% | 427,589 (+19.62%) | Filing |